earticle

논문검색

Recent Trends in Antibody Engineering and Therapeutics, Chair : Yong-Sung Kim (Ajou Univ., Korea)

Development of TanibirumabTM, anti-KDR neutralizing fully human antibody and next generation DIG-bodiesTM and PIG-bodiesTM

초록

영어

I will discuss about our preclinical data of anti-KDR neutralizing fully human IgG1, Tanibirumab which has cross-species cross reactivity, and about our recent progress from dual target neutralizing multifunctional Ig like next generation protein therapeutics, DIG-KT (KDR &Tie2) from DIG-bodies platform, and PIG-KM (KDR &cMET) from PIG-bodies platform.

저자정보

  • Jin-San YOO Chief Executive officer, Pharmabcine Inc.,Korea

참고문헌

자료제공 : 네이버학술정보

    함께 이용한 논문

      ※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.

      0개의 논문이 장바구니에 담겼습니다.